Shire competitors

Shire's competitors include Alexion Pharmaceuticals, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Biogen, Celgene Corporation and Gilead Sciences
Add company...
Shire
Shire is a specialty biopharmaceutical company.
Alexion Pharmaceuticals
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Biogen
Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.
Celgene Corporation
Celgene Corporation is a biopharmaceutical company.
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Founding Date
Founding Date
1986
Founding Date
1992
Founding Date
1988
Founding Date
1989
Founding Date
1978
Founding Date
1986
Founding Date
1987
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Dublin, IE HQ
Buenos Aires, AR
Sydney, AU
Wien, AT
Bruxelles, BE
Chácara Santo Antonio (Zona Sul), BR
Sofia, BG
see more
Locations
New Haven, US HQ
Buenos Aires, AR
Sydney, AU
Vienna, AT
Brussels, BE
São Paulo, BR
Toronto, CA
see more
Locations
Tarrytown, US HQ
Dublin, IE
Limerick, IE
Greater London, GB
Rensselaer, US
Bernards, US
Locations
Boston, US HQ
Locations
Cambridge, US HQ
Locations
Summit, US HQ
Singapore, SG
Boudry, CH
Locations
Foster City, US HQ
Fremont, US
Oceanside, US
San Dimas, US
Branford, US
Seattle, US
Employees
Employees
23,0444% decrease
Employees
2,52519% decrease
Employees
6,20015% increase
Employees
2,3007% increase
Employees
7,3001% decrease
Employees
7,4675% increase
Employees
9,000
Valuation ($)
Valuation ($)
52.3 b
Valuation ($)
26.1 b
Valuation ($)
40.2 b
Valuation ($)
44.7 b
Valuation ($)
69.1 b
Valuation ($)
63.4 b
Valuation ($)
98 b
Facebook likes
Facebook likes
N/A
Facebook likes
N/A
Facebook likes
3.9 k
Facebook likes
N/A
Facebook likes
3.1 k
Facebook likes
6.6 k
Facebook likes
5.4 k
Twitter followers
Twitter followers
6.2 k
Twitter followers
1.8 k
Twitter followers
12.6 k
Twitter followers
32.9 k
Twitter followers
19.4 k
Twitter followers
19.1 k
Twitter followers
27 k

Financial

Revenue (est.)
Revenue (est.)
$15.2b (FY, 2017)
Revenue (est.)
$3.1b (FY, 2016)
Revenue (est.)
$4.9b (FY, 2016)
Revenue (est.)
$2.5b (FY, 2017)
Revenue (est.)
$11.4b (FY, 2016)
Revenue (est.)
$13b (FY, 2017)
Revenue (est.)
$26.1b (FY, 2017)
Cost of goods
Cost of goods
$4.7b (FY, 2017)
Cost of goods
$258m (FY, 2016)
Cost of goods
$194.6m (FY, 2016)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$461m (FY, 2017)
Cost of goods
$4.4b (FY, 2017)
Gross profit
Gross profit
$10.5b (FY, 2017)
Gross profit
$2.8b (FY, 2016)
Gross profit
$4.7b (FY, 2016)
Gross profit
N/A
Gross profit
N/A
Gross profit
$12.5b (FY, 2017)
Gross profit
$21.7b (FY, 2017)
Net income
Net income
$4.3b (FY, 2017)
Net income
$399m (FY, 2016)
Net income
$895.5m (FY, 2016)
Net income
$91.6m (FY, 2017)
Net income
$3.7b (FY, 2016)
Net income
$2.9b (FY, 2017)
Net income
$4.6b (FY, 2017)

Operating

Countries
Countries
100 (FY, 2017)
Countries
N/A
Countries
N/A
Countries
N/A
Countries
N/A
Countries
N/A
Countries
30 (FY, 2016)
Phase I Trials Products
Phase I Trials Products
7 (FY, 2017)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
4 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
3 (FY, 2016)
Phase II Trials Products
Phase II Trials Products
10 (FY, 2017)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
10 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
12 (FY, 2016)
Phase III Trials Products
Phase III Trials Products
15 (FY, 2017)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
6 (FY, 2016)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 8.9m
Total funding raised
$ 2.4m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Alexion Pharmaceuticals
HQ
New Haven, US
Employees
2,525↓ 19% decrease

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases.

View company
Regeneron Pharmaceuticals
HQ
Tarrytown, US
Employees
6,200↑ 15% increase

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

View company
Vertex Pharmaceuticals
HQ
Boston, US
Employees
2,300↑ 7% increase

Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.

View company
Biogen
HQ
Cambridge, US
Employees
7,300↓ 1% decrease

Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.

View company